骨髓瘤IX与骨髓瘤XI两项3期随机对照试验中接受治疗的多发性骨髓瘤患者的血栓形成
基于骨髓瘤IX(n=1936)和骨髓瘤XI(n=4358)两项3期随机对照试验,分析新诊断多发性骨髓瘤患者的血栓结局。骨髓瘤IX中CVAD方案VTE风险高于CTD(22.5% vs 16.1%;aHR 1.46),CTDa方案VTE风险高于MP(16.0% vs 4.1%;aHR 4.25);骨髓瘤XI中CRD与CTD的VTE风险无差异,但CRDa动脉血栓风险高于CTDa(3.1% vs 1.6%;aHR 1.91)。血栓事件几乎均发生于治疗开始后6个月内。
要点
- 骨髓瘤IX中,适合移植者CVAD诱导的VTE风险高于CTD(22.5% vs 16.1%;aHR 1.46)。
- 骨髓瘤XI中,不适合移植者CRDa的动脉血栓风险高于CTDa(3.1% vs 1.6%;aHR 1.91)。
- 骨髓瘤XI中血栓预防率高于骨髓瘤IX(80.5% vs 22.3%),相同方案VTE率更低。
核心结论
- 尽管采用IMWG指导的血栓预防,血栓形成仍频繁发生,提示需要新方法。
研究设计与样本
- 骨髓瘤IX(n=1936)和骨髓瘤XI(n=4358)两项3期随机对照试验,纳入新诊断多发性骨髓瘤患者,覆盖适合与不适合移植者,治疗时间在血栓预防指南发布前后。
主要发现
- 骨髓瘤IX适合移植者:CVAD组VTE 22.5%(121/538)vs CTD组16.1%(89/554),aHR 1.46(95%CI 1.11-1.93)。
- 骨髓瘤IX不适合移植者:CTDa组VTE 16.0%(68/425)vs MP组4.1%(17/419),aHR 4.25(95%CI 2.50-7.20)。
- 骨髓瘤XI适合移植者:CRD组VTE 12.2%(124/1014)vs CTD组13.2%(133/1008),aHR 0.92(95%CI 0.72-1.18);动脉血栓1.2%(12/1014)vs 1.5%(15/1008),aHR 0.80(95%CI 0.37-1.70)。
- 骨髓瘤XI不适合移植者:CRDa组VTE 10.4%(95/916)vs CTDa组10.7%(97/910),aHR 0.97(95%CI 0.73-1.29);动脉血栓CRDa组3.1%(28/916)vs CTDa组1.6%(15/910),aHR 1.91(95%CI 1.02-3.57)。
- 骨髓瘤XI中动脉事件患者OS更差(aHR 1.53;95%CI 1.12-2.08);血栓事件几乎均发生于治疗开始后6个月内。
关键数值与推荐
- 骨髓瘤XI试验方案纳入IMWG血栓预防推荐;与骨髓瘤IX相比,更多患者接受血栓预防(80.5% vs 22.3%),相同方案VTE率更低(CTD 13.2% vs 16.1%;CTDa 10.7% vs 16.0%)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Newly diagnosed multiple myeloma (NDMM) patients treated with immunomodulatory drugs are at high risk of venous thromboembolism (VTE), but data are lacking from large prospective cohorts. We present thrombosis outcome data from Myeloma IX (n = 1936) and Myeloma XI (n = 4358) phase 3 randomized controlled trials for NDMM that treated transplant-eligible and transplant-ineligible patients before and after publication of thrombosis prevention guidelines. In Myeloma IX, transplant-eligible patients randomly assigned to cyclophosphamide, vincristine, doxorubicin, and dexamethasone (CVAD) induction had higher risk of VTE compared with patients treated with cyclophosphamide, thalidomide, and dexamethasone (CTD) (22.5% [n = 121 of 538] vs 16.1% [n = 89 of 554]; adjusted hazard ratio [aHR],1.46; 95% confidence interval [95% CI], 1.11-1.93). For transplant-ineligible patients, those randomly assigned to attenuated CTD (CTDa) induction had a higher risk of VTE compared with those treated with melphalan and prednisolone (MP) (16.0% [n = 68 of 425] vs 4.1% [n = 17 of 419]; aHR, 4.25; 95% CI, 2.50-7.20). In Myeloma XI, there was no difference in risk of VTE (12.2% [n = 124 of 1014] vs 13.2% [n = 133 of 1008]; aHR, 0.92; 95% CI, 0.72-1.18) or arterial thrombosis (1.2% [n = 12 of 1014] vs 1.5% [n = 15 of 1008]; aHR, 0.80; 95% CI, 0.37-1.70) between transplant-eligible pathways for patients treated with cyclophosphamide, lenalidomide, and dexamethasone (CRD) or CTD. For transplant-ineligible patients, there was no difference in VTEs between attenuated CRD (CRDa) and CTDa (10.4% [n = 95 of 916] vs 10.7% [n = 97 of 910]; aHR, 0.97; 95% CI, 0.73-1.29). However, arterial risk was higher with CRDa than with CTDa (3.1% [n = 28 of 916] vs 1.6% [n = 15 of 910]; aHR, 1.91; 95% CI, 1.02-3.57). Thrombotic events occurred almost entirely within 6 months of treatment initiation. Thrombosis was not associated with inferior progression-free survival (PFS) or overall survival (OS), apart from inferior OS for patients with arterial events (aHR, 1.53; 95% CI, 1.12-2.08) in Myeloma XI. The Myeloma XI trial protocol incorporated International Myeloma Working Group (IMWG) thrombosis prevention recommendations and compared with Myeloma IX, more patients received thromboprophylaxis (80.5% vs 22.3%) with lower rates of VTE for identical regimens (CTD, 13.2% vs 16.1%; CTDa, 10.7% vs 16.0%). However, thrombosis remained frequent in spite of IMWG-guided thromboprophylaxis, suggesting that new approaches are needed.
引用
- Bradbury CA, Craig Z, Cook G, et al. Thrombosis in patients with myeloma treated in the Myeloma IX and Myeloma XI phase 3 randomized controlled trials. Blood. 2020. PMID: 32438407. doi:10.1182/blood.2020005125
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。